Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Nuo Therapeutics, Inc.
- Market Cap
- Unavailable
- Price
- $1.03
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.00%
- Volume
- 1.2K
About
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Quick stats
Shares outstanding—
Computed float20.2M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001091596
Websitehttps://www.nuot.com
AI Summary
AI-generated1/3
standardbullishearnings
Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Nuo Therapeutics reported Q2 revenue of approximately $1.77 million, representing growth of over 150% year-over-year and 38% sequentially, driven by strong Aurix product sales.
The company significantly narrowed its net operating loss to roughly $167,000, an improvement of $280,000 from the prior quarter, supported by a favorable reimbursement landscape for autologous PRP therapies.
Management amended a loan agreement to secure $675,000 in interim funding and confirmed the achievement of a reimbursement fee milestone, with payment expected in the current quarter.
Red flags
- Company remains unprofitable with a net loss of $277,601 in Q2
- Accumulated deficit stands at $35.7 million
- Relies on external debt financing to fund working capital